A new study published in JAMA Pediatrics reveals that gender-affirming medications, such as puberty blockers and hormone treatments, are far less common among US adolescents than critics suggest. The study, analyzing insurance claims for over 5 million adolescents, found that fewer than 1 in 1,000 received these treatments between 2018 and 2022. Researchers emphasize that these findings contradict claims of widespread access to such care and highlight the need for accurate information in the ongoing debate surrounding transgender healthcare.
As debates over transgender healthcare intensify across the United States, a new study offers clarity, revealing that gender-affirming medications are far less common than critics claim. Published Monday in JAMA Pediatrics, the study found that fewer than 1 in 1,000 U.S. adolescents received puberty blockers or hormone treatments between 2018 and 2022.The researchers analyzed a database of insurance claims for over 5 million adolescents aged 8 to 17 with commercial insurance plans.
The U.S. Supreme Court is expected to rule on the issue later this year, with implications for similar cases nationwide.President-elect Donald Trump has pledged to roll back protections for transgender people, further politicizing the topic.Medical professionals argue that gender-affirming care is applied cautiously, guided by individual needs and expert oversight. Dr.
Transgender Healthcare Puberty Blockers Hormone Treatments Adolescents Study Findings
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
US Study Finds Low Rate of Gender-Affirming Care for Transgender YouthA new study published in JAMA Pediatrics reveals that the rate of gender-affirming medical care for transgender youth is significantly lower than previously thought.
Read more »
Study Finds Low Use of Gender-Affirming Medications Among US YouthA new study published in JAMA Pediatrics reveals that fewer than 1 in 1,000 adolescents with commercial insurance received gender-affirming medications (puberty blockers or hormones) between 2018 and 2022.
Read more »
Few US Teens with Private Insurance Receive Gender-Affirming Care, Study FindsA new study reveals that less than 0.1% of teenagers with private insurance in the US who have been diagnosed with gender dysphoria are receiving puberty blockers or cross-sex hormones. The findings shed light on the impact of recent state bans on gender-affirming care.
Read more »
Study Finds Very Few Youth Use Gender-Affirming MedicationsA new analysis of private insurance claims reveals that less than 0.1% of youth accessed puberty blockers or hormones for gender transition, despite significant attention from Republican lawmakers.
Read more »
Few US Youth Seek Gender-Affirming Care, Study FindsA new study analyzing private insurance claims data reveals that less than 0.1% of US youth accessed puberty blockers or hormones for gender transition.
Read more »
Study Finds Less Than 0.1% of US Youth Use Gender-Affirming MedicationsA new analysis of private insurance claims data reveals that a very small percentage of youth in the United States use puberty blockers or hormones for gender transition. This finding comes amid increasing political scrutiny of transgender youth and their access to healthcare.
Read more »